Last reviewed · How we verify
NCT05390021
PET/MRI in Endometrial Cancer
NA trial testing PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent in Cytoreductive Surgery. Withdrawn.
1 February 2025
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 30 March 2024 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2026 |
Drugs / interventions tested
- PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent
Conditions studied
- Cytoreductive Surgery — all drugs for Cytoreductive Surgery →
- Grade 3 Endometrial Endometrioid Adenocarcinoma — all drugs for Grade 3 Endometrial Endometrioid Adenocarcinoma →
- High Grade Serous Carcinoma — all drugs for High Grade Serous Carcinoma →
- Endometrial Undifferentiated Carcinoma — all drugs for Endometrial Undifferentiated Carcinoma →
Sponsor
Massachusetts General Hospital
Who can join
Adults 18 to 85, female only, with Cytoreductive Surgery or Grade 3 Endometrial Endometrioid Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography \[CT\], or PET/CT) for high-risk endometrial cancer. The name of the intervention involved in this study is: Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Update on PET/MRI in Gynecological Malignancies-A Review of the Literature.
Virarkar M, Vulasala SS, Calimano-Ramirez L, Singh A, et al · · 2023 · cited 5× · PMID 36661732 · DOI 10.3390/curroncol30010083
Verify or expand the search:
- PubMed search for NCT05390021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cytoreductive Surgery
Currently open trials in the same condition.
- NCT05597683 — Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy · NA · recruiting
- NCT05316181 — CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) · Phase 3 · active not recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05390021 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 2 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05390021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing